Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07228559 · ClinicalTrials.gov registry record · Phase 1
A Study of Avoralstat In Participants With Diabetic Macular Edema
A Phase 1 study of Diabetic Macular Edema (DME), sponsored by BioCryst Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 8
- Study locations
NCT07228559 is a Phase 1 study of Diabetic Macular Edema (DME) that is actively recruiting participants, run by BioCryst Pharmaceuticals. The registered enrollment target is 9 participants, below the 361-participant average among 8 other Diabetic Macular Edema (DME) trials with a reported enrollment target (98% lower). The trial reports 8 study locations across 5 states.
The verdict
NCT07228559, a Phase 1 study of Diabetic Macular Edema (DME), is actively recruiting participants, sponsored by BioCryst Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 8
- Study locations
Study Summary
The goal of this study is to assess the safety and therapeutic potential of a single dose of avoralstat in adult participants with DME.
Conditions Studied
Interventions
- DRUG avoralstat
Study Locations (8)
New South Wales
- Investigative Site 1 - Sydney
- Investigative Site 2 - Sydney
- Investigative Site 3 - Sydney
Texas
- Investigative Site 7 - Katy
- Investigative Site 8 - The Woodlands
California
- Investigative Site 6 - Sacramento
South Australia
- Investigative Site 4 - Adelaide
Victoria
- Investigative Site 5 - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2025-10-02 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07228559
The ClinicalTrials.gov registry entry for NCT07228559 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 361-participant average among 8 other Diabetic Macular Edema (DME) trials with a reported enrollment target (98% lower). The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Macular Edema (DME) appearing as the primary indexed condition, and to 1 intervention - of which avoralstat is the first listed.
NCT07228559 reports 8 study locations spanning 5 distinct geographic areas - top geographies include New South Wales, Texas, California.
Frequently Asked Questions
What is clinical trial NCT07228559 about?
NCT07228559 is a clinical study titled "A Study of Avoralstat In Participants With Diabetic Macular Edema". The goal of this study is to assess the safety and therapeutic potential of a single dose of avoralstat in adult participants with DME.
What is the current status of trial NCT07228559?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2025-10-02. Estimated completion is 2026-09.
What conditions does trial NCT07228559 study?
This clinical trial studies the following conditions: Diabetic Macular Edema (DME).
What interventions are being tested in trial NCT07228559?
The interventions under investigation include: avoralstat (DRUG).
Who is sponsoring clinical trial NCT07228559?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07228559 being conducted?
This trial has 8 study locations across California, Texas, New South Wales, South Australia, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema (DME)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
COMPLETED · Phase 1
-
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
RECRUITING · Phase 4
-
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
-
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
-
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.